US4497826A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antiparkinsonian agent
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1982-09-08
•
Granted: 1985-02-05
•
Expires: 2002-09-08
Abstract
Abstract An antiparkinsonian agent comprising DL- or L-threo-3,4-dihydroxyphenylserine and a decarboxylase inhibitor (e.g. carbidopa and benserazide), which is useful for the treatment of parkinson's disease, particularly treatment of the freezing phenomenon which has not previously been cured by the conventional antiparkinsonian drugs such as L-DOPA.
Inventors
- 👤 Hirotaro Narabayashi
- 👤 Tomoyoshi Kondo
- 👤 Akira Hayashi
- 👤 Tomokazu Suzuki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 04:53
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61P; A61P25/00; A61P25/02
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
66 words
A method for treating parkinson's disease, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof and from about 0.025 to about 0.50 mole to 1 mole of said DL- or L-threo-3,4-dihydroxyphenylserine of a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa to a patient suffering from parkinson's disease.
Claim 2
Independent Claim
66 words
A method for treating parkinson's disease, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof and from about 0.025 to about 0.50 mole to 1 mole of said DL- or L-threo-3,4-dihydroxyphenylserine of a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa to a patient suffering from parkinson's disease.
Claim 3
Dependent Claim
30 words
A method according to claim 1, wherein said DL- or L-threo-3,4-dihydroxyphenylserine or said salt thereof is orally administered in an amount of from about 0.1 to 4 g per day.
Claim 4
Dependent Claim
28 words
A method according to claim 1, wherein said threo-3,4-dihydroxyphenylserine or said salt thereof is intravenously administered in an amount of from about 0.1 to 1 g per day.
Claim 5
Dependent Claim
20 words
A method according to claim 1, 2 or 3, wherein the decarboxylase inhibitor is carbidopa, benserazide or the hydrochloride benserazide.
Claim 6
Independent Claim
86 words
A method for treating parkinson's disease in a patient for whom treatment with L-DOPA and a decarboxylase inhibitor is substantially ineffective, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydrophenylserine or a pharmaceutically acceptable acid addition salt thereof and a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa to a patient suffering from parkinson's disease, said decarboxylase inhibitor being used in an amount of 0.025 to 0.5 mole to 1 mole of the DL- or L-threo-3,4-dihydroxyphenylserine.
Claim 7
Independent Claim
86 words
A method for treating parkinson's disease in a patient for whom treatment with L-DOPA and a decarboxylase inhibitor is substantially ineffective, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydrophenylserine or a pharmaceutically acceptable acid addition salt thereof and a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa to a patient suffering from parkinson's disease, said decarboxylase inhibitor being used in an amount of 0.025 to 0.5 mole to 1 mole of the DL- or L-threo-3,4-dihydroxyphenylserine.
Claim 8
Dependent Claim
28 words
A method according to claim 5, wherein DL- or L-threo-3,4-dihydroxyphenylserine or said salt thereof is orally administered in an amount of from 0.1 to 4 g per day.
Claim 9
Dependent Claim
24 words
A method according to claim 5, wherein said threo-3,4-dihydrophenylserine is intravenously administered in an amount of from about 0.1 to 1 g per day.
Claim 10
Dependent Claim
21 words
A method according to claim 5, 6 or 7, wherein the decarboxylase inhibitor is carbidopa, benserazide or the hydrochloride of benserazide.
Claim 11
Dependent Claim
63 words
An antiparkinsonian pharmaceutical composition comprising a pharmaceutically effective amount of DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof and a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa, said decarboxylase inhibitor being contained in an amount of from about 0.025 to about 0.5 mole to 1 mole of said DL- or L-threo-3,4-dihydroxyphenylserine.
Claim 12
Dependent Claim
63 words
An antiparkinsonian pharmaceutical composition comprising a pharmaceutically effective amount of DL- or L-threo-3,4-dihydroxyphenylserine or a pharmaceutically acceptable acid addition salt thereof and a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa, said decarboxylase inhibitor being contained in an amount of from about 0.025 to about 0.5 mole to 1 mole of said DL- or L-threo-3,4-dihydroxyphenylserine.
Claim 13
Dependent Claim
18 words
A composition according to claim 9, wherein said decarboxylase inhibitor is carbidopa benserazide or the hydrochloride of benserazide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-02-05 | 1988-08-06 | 1989-02-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-02-05 | 1992-08-06 | 1993-02-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-02-05 | 1996-08-06 | 1997-02-05 | $7700.00 | Window Closed / Lapsed |